Iovance Biotherapeutics, Inc. (IOVA)
| Previous close | 12.03 |
| Open | 11.86 |
| Bid | 12.36 x 700 |
| Ask | 12.43 x 700 |
| Day's range | 11.70 - 12.48 |
| 52-week range | 3.21 - 18.33 |
| Volume | |
| Avg. volume | 8,878,448 |
| Market cap | 3.462B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.00 |
GlobeNewswireIovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit Fireside Chat: April 30, 2024 at 2:30 p.m. ETVirtual The Citizens JMP Life Scienc
Simply Wall St.With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
Insider Monkey20 Counties with the Highest Cancer Rates in the US
In this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact of cancer, head straight to the 5 Counties with the Highest Cancer Rates in the US. Confronting Cancer: Global Impact and Trends in […]
